Drugs Made in America Acquisition Corp. (NASDAQ:DMAAU) announced the pricing of its $200 million IPO and its units are expected to begin trading on the Nasdaq under the symbol “DMAAU”, Tuesday, January 28, 2025.
The new SPAC intends to combined with a target company in the pharmaceutical industry that has products derived from plant-based raw materials.
Drugs Made in America’s sponsor team is led by Chief Executive Officer and Executive Chair Lynn Stockwell, and Chief Financial Officer Glenn Worman. Catherine Do, Sridhar Prasad and Myron W. Shulgan will serve on its Board of Directors.
Total SPAC deal count for 2025 year-to-date is now 6. This offering is expected to close on Wednesday, January 29, 2025.
Clear Street is acting as the sole book-running manager in the offering. Loeb & Loeb LLP is serving as Issuer’s Counsel with Winston & Strawn LLP serving as Underwriter’s Counsel. MaloneBailey LLP serves as auditor. Wilmington Trust, National Association is acting as trustee.
Crown PropTech (OTC:CPTKW) has entered into a definitive agreement to combine with rare earth mining firm Mkango Resources (TSX-V:MKA) at a pre-money equity value of $400 million. London-based Mkango is working to commercialize a chain of rare earth mining and refining facilities in Africa and Europe. The combined company is expected to trade on the...
At the SPAC of Dawn One of the biggest sources of uncertainty in the SPAC market in recent years has been regulatory changes, but new shifts could be in its favor. SEC Chairman Paul Atkins told CNBC yesterday that the commission would review the rules for SPACs after “rather controversial” changes to the rules passed...
McKinley Acquisition Corporation (NASDAQ:MKLYU) has filed for a $150 million SPAC to hunt for an innovative target company with an experienced financial team that has dabbled in SPACs before. The new SPAC is offering investors one right to a 1/10 share in each unit with no overfunding of the trust, but it could provide a...
At the SPAC of Dawn The rain of SPACs has continued with four expected to make their debuts during today’s trading sessions after pricing their IPOs overnight. The largest of these, EQV Ventures II (NASDAQ:EVACU), even managed an upsize, making it the largest SPAC IPO since Ares II (NYSE:AACT) pulled together $450 million in 2023....
EQV Ventures II (NASDAQ:EVACU) announced the pricing of its upsized $420 million IPO and its units are expected to begin trading on the Nasdaq under the symbol “EVACU”, Wednesday, July 2, 2025. The new SPAC plans to merge with an energy target involved in upstream exploration or production. EQV II’s management team is led by...